Endpoints delivers live journalism at the industry’s most important gatherings and contributes industry-leading programming through our franchise productions. To learn more about brand alignment and lead-gen opportunities at our events, use the below contact button to reach our sales team.
An Endpoints Day focused on drug commercialization, featuring a panel hosted by an Endpoints journalist with more sessions to be announced. This event will focus on trends in drug launches, marketing and sales.
A special feature covering the latest in pharma innovation, manufacturing and development.
Cell & Gene Therapy Day will convene a series of expert panels to find out where the field stands today and explore funding, development and launch strategies to plot the path to commercialization.
The Financial Times US Pharma and Biotech Summit returns to New York in May, partnered with Endpoints News. The event will gather biopharma leaders, regulators, investors and scientists to share unique insights about the year ahead and discuss the most important trends affecting the industry, and the country.
There’s a new emphasis on bringing innovative medicines to the Japanese market – how can your biopharma take the next steps? Join Endpoints in a discussion with senior Japanese leaders, and hear firsthand perspectives on the regulatory and pricing dynamics behind one of the world’s top pharma markets. This is part of Endpoints’ ongoing series with PMDA officials — Japan’s regulatory body — and experienced Japanese pharma execs.
Developing a biopharma drug and want to enter Japan? Please join our discussion.
Pharmaceutical manufacturing is under a heavy spotlight. Policymakers are focused on the relationships between pharma companies and their manufacturing partners, and high-demand medications are stretching the limits of production. Join Endpoints for sessions focused on the latest trends and pressure points, and hear how leading experts are reacting to a fast-changing landscape.
We’re back with this year’s selection of the top eleven most promising biotechs. They’re taking big swings with cutting-edge science and proven leadership, and the industry is watching to see if they succeed — or fail. Either way, they’ll be bellwethers for where biotech is heading.
Join a select group of industry leaders for this year’s awards gala in Downtown Boston for an evening of dinner, drinks and networking to meet the future of biotech.
Each year, Endpoints recognizes and honors women leaders in the biopharma industry — key figures in the industry who are blazing a trail and pushing gender diversity forward. Join us to celebrate this year’s honorees and become a part of our community of women leaders.
AI is everywhere in the biopharma industry. Every company, from the biggest global pharma to the tiniest biotech, is experimenting with the technology. But what’s hype, and what’s reality? We’re bringing together AI evangelists and skeptics alike to chart out the places AI is most likely to push the industry forward.
After a pandemic rush on telehealth and direct-to-consumer care, the dust is settling — and the market is saturated. Both new start-ups and legacy pharma companies started going direct to patients, with varying degrees of success. Join us at HLTH as we take a look at what aspects are stable, which are still trying to find footing, and make our predictions for long-term trends.
What’s in store for the future of R&D in Europe? The Financial Times' Global Pharma Biotech Summit, held in London in collaboration with Endpoints News, will chart the waters ahead this year and beyond — covering drug development, financing trends, regulatory issues and more on topics central to the biopharma industry. Join us there or tune into our virtual sessions.
We’re closing out the year’s conferences at ASH, where we’ll take a close look at the latest developments in blood disorder diagnosis and treatment. Join us as we talk with leading experts about the major news out of the event.
We’ve asked our advisory group in the E100 about how things are shaping up at the FDA and HHS under the new Trump administration and what impact prospective changes could have on the drug development industry. Also, they have insights on the tense China-US relations and drug development, AI and our continuing focus on financing at a critical crossroads for biopharma.
Join Endpoints for a series of conversations on the latest trends in clinical trials in the US and abroad, the regulatory environment, and how expectations from the industry and beyond are shifting the trial strategies of the future.
Every year Chris Dokomajilar at DealForma and Endpoints founding editor John Carroll collaborate on identifying the top 100 biotech VCs in operation, based on the total amount invested in new rounds. This year, we’re bringing together a group of top experts in the field to discuss the key trends affecting one of the most consequential sources of money for biotech startups. Who’s a player? And how are IPOs and M&A likely to work in the year ahead? Join us.
An Endpoints Day focused on drug discovery, featuring a panel session hosted by an Endpoints journalist with more sessions to be announced. This event will focus on research pipelines, emerging drug targets and the inflection point of research to development.
An event with future-focused conversations about the emerging science and technology that will power the major drugs and companies of tomorrow.
For well over 15 years Endpoints founding editor John Carroll has written an annual report on the top 15 global pharma companies’ R&D budgets, analyzing their pipelines and reviewing their potential — or lack thereof. This year, he’s also assembling a panel of research experts to help review results and parse strategies for a massively influential segment of the industry’s research ops. Where are the top 15 companies in biopharma headed and how will that affect the entire industry? Join us to find out.
